{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    46,
    47,
    49,
    50,
    51,
    54,
    57,
    58,
    59,
    60,
    63,
    66,
    67,
    68,
    70,
    73,
    74,
    76,
    77
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "first dose \nof study treatment"
      },
      {
        "id": "anchor_3",
        "definition": "Day 1 of Cycle 1",
        "anchorType": "CycleStart",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Cycle 1 Day 1"
      },
      {
        "id": "anchor_llm_1",
        "definition": "Point/time of patient entry into the study; the point at which informed consent must be obtained (i.e. prior to starting any of the procedures described in the protocol)",
        "anchorType": "Enrollment",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Enrollment: Point/time of patient entry into the study; the point at which informed consent must be obtained (i.e. prior to starting any of the procedures described in the protocol)"
      },
      {
        "id": "anchor_2",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "informed consent"
      },
      {
        "id": "anchor_4",
        "definition": "procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_20",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "QD"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "BID"
      },
      {
        "id": "rep_cycle_1",
        "type": "Cycle",
        "sourceText": "Cycle 1 Day 8"
      },
      {
        "id": "rep_cycle_2",
        "type": "Cycle",
        "sourceText": "Cycle 1 Day 15"
      },
      {
        "id": "rep_cycle_3",
        "type": "Cycle",
        "sourceText": "Cycle \n4 Day 1"
      },
      {
        "id": "rep_cycle_4",
        "type": "Cycle",
        "sourceText": "Cycle 22 Day 1"
      },
      {
        "id": "rep_cycle_5",
        "type": "Cycle",
        "sourceText": "C1D1"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "Treatment period"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "sourceText": "treatment \nperiod"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "sourceText": "follow-up period"
      },
      {
        "id": "rep_window_5",
        "type": "Continuous",
        "sourceText": "follow up period"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "sourceText": "observation period"
      },
      {
        "id": "rep_window_8",
        "type": "Continuous",
        "sourceText": "30 days after"
      },
      {
        "id": "rep_window_9",
        "type": "Continuous",
        "sourceText": "120 \ndays after"
      },
      {
        "id": "rep_window_11",
        "type": "Continuous",
        "sourceText": "150 days after"
      },
      {
        "id": "rep_llm_1",
        "type": "Cycle",
        "startOffset": "P0D",
        "interval": "P21D",
        "exitCondition": "final PFS analysis",
        "sourceText": "Visit evaluation schedule: Safety run-In part (Part 1) – visit schedule updated and applicable following final PFS analysis"
      },
      {
        "id": "rep_llm_2",
        "type": "Cycle",
        "startOffset": "P0D",
        "interval": "P21D",
        "exitCondition": "final PFS analysis",
        "sourceText": "Visit evaluation schedule: Biomarker cohort (Part 2) – visit schedule updated and applicable following final PFS analysis"
      },
      {
        "id": "rep_llm_3",
        "type": "Cycle",
        "startOffset": "P0D",
        "interval": "P21D",
        "exitCondition": "final PFS analysis",
        "sourceText": "Visit evaluation schedule: Double-blind, randomized, placebo-controlled part (Part 3) – visit schedule updated and is applicable following final PFS analysis"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_crossover_1",
        "requiredSequence": [
          "SCREENING",
          "PERIOD_1",
          "PERIOD_2",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Day 1",
          "End of Study"
        ],
        "sourceText": "crossover"
      },
      {
        "id": "traversal_1",
        "requiredSequence": [
          "MOLECULAR_PRE_SCREENING",
          "SCREENING",
          "TREATMENT_PHASE",
          "END_OF_TREATMENT",
          "SAFETY_FOLLOW_UP",
          "EFFICACY_FOLLOW_UP",
          "SURVIVAL_FOLLOW_UP"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "End of Study",
          "Molecular Pre-screening",
          "Safety Follow-up Visit",
          "End of Treatment Visit",
          "Day 1"
        ],
        "sourceText": "[{'condition': 'Subject experiences toxicity or Adverse Event', 'path': ['TREATMENT_DISCONTINUATION', 'FOLLOW_UP_FOR_TOXICITIES', 'SAFETY_FOLLOW_UP']}, {'condition': 'Subject discontinues treatment for reasons other than disease progression', 'path': ['EFFICACY_FOLLOW_UP', 'SURVIVAL_FOLLOW_UP']}, {'condition': 'Subject withdraws consent', 'path': ['WITHDRAWAL_OF_STUDY_CONSENT', 'LOST_TO_FOLLOW_UP']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Ecg",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 11"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 2"
      },
      {
        "activityId": "Laboratory Test",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Dosing",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 2"
      },
      {
        "activityId": "Imaging",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Tissue Sample",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Questionnaire",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Screening phase",
        "executionType": "Single",
        "rationale": "The screening phase is described as a discrete initial period to determine eligibility prior to study entry."
      },
      {
        "activityId": "Treatment phase",
        "executionType": "Single",
        "rationale": "The treatment phase involves scheduled administration and assessments at specific intervals (visits) throughout the study duration."
      },
      {
        "activityId": "Safety follow-up",
        "executionType": "Single",
        "rationale": "Safety follow-up is typically a one-time assessment occurring after the end of treatment to monitor for delayed adverse events."
      },
      {
        "activityId": "Efficacy follow-up",
        "executionType": "Single",
        "rationale": "Efficacy follow-up involves repeated assessments over time to monitor disease progression or response after the treatment phase."
      },
      {
        "activityId": "Public health emergency mitigation procedures",
        "executionType": "Single",
        "rationale": "These procedures are conditional workflows triggered only if a public health emergency occurs during the study."
      }
    ],
    "crossoverDesign": {
      "id": "crossover_1",
      "isCrossover": true,
      "numPeriods": 2,
      "numSequences": 2,
      "periods": [
        "Period 1",
        "Period 2"
      ],
      "sequences": [
        "AB",
        "BA"
      ],
      "washoutRequired": false,
      "sourceText": "crossover"
    },
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "procedure_conditional",
        "text": "For Cycle 1, all assessments have a ± 3 day window unless otherwise indicated.",
        "footnoteId": "fn_1",
        "structuredCondition": "cycle == 1 ? window(P3D) : null",
        "appliesToActivityIds": [
          "all"
        ],
        "sourceText": "For Cycle 1, all assessments have a ± 3 day window unless otherwise indicated."
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_after",
        "text": "After Cycle 1, all assessments have a ± 7 day window, unless otherwise indicated.",
        "footnoteId": "fn_2",
        "structuredCondition": "cycle > 1 ? window(P7D) : null",
        "appliesToActivityIds": [
          "all"
        ],
        "sourceText": "After Cycle 1, all assessments have a ± 7 day window, unless otherwise indicated."
      },
      {
        "id": "fn_cond_3",
        "conditionType": "sequence",
        "text": "If study drug is being held due to toxicity, then the scheduled visits and assessments should still be performed per protocol.",
        "footnoteId": "fn_3",
        "structuredCondition": "if(drug_hold == true) { perform_assessments = true }",
        "appliesToActivityIds": [
          "all"
        ],
        "sourceText": "If study drug is being held due to toxicity, then the scheduled visits and assessments should still "
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_after",
        "text": "Following final PFS analysis; colour digital photography assessments are no longer required.",
        "footnoteId": "fn_4",
        "structuredCondition": "if(pfs_analysis_complete == true) { activity_required = false }",
        "appliesToActivityIds": [
          "colour digital photography"
        ],
        "sourceText": "Following final PFS analysis; colour digital photography assessments are no longer required."
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "Suspected AEs up to Day 150; non-suspected AEs up to Day 150 or start of new post treatment anti-neoplastic medication, whichever is sooner.",
        "footnoteId": "fn_5",
        "structuredCondition": "if(ae_type == 'suspected') { monitor_until(D150) } else { monitor_until(min(D150, start_new_therapy)) }",
        "appliesToActivityIds": [
          "AE monitoring"
        ],
        "sourceText": "Suspected AEs up to Day 150; non-suspected AEs up to Day 150 or start of new post treatment anti-neo"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Progression-Free Survival (PFS)",
        "endpointType": "Primary",
        "inputs": [
          "Date of randomization",
          "Date of first documented progression",
          "Date of death",
          "Investigator assessment (RECIST)"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "Until progression or death"
        },
        "algorithm": "Time from randomization to the first documented progression or death due to any cause",
        "successCriteria": "Statistically significant improvement in PFS (P-value < alpha) for PDR001 combination vs. placebo combination",
        "sourceText": "The final Progression-Free Survival (PFS) analysis occurred using a data cut-off date of 01-Jul-2020... the study did not meet its primary endpoint of investigator-assessed PFS."
      },
      {
        "id": "ep_2",
        "name": "Key Secondary: Overall Survival (OS)",
        "endpointType": "Secondary",
        "inputs": [
          "Date of randomization",
          "Date of death"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "Until death"
        },
        "algorithm": "Time from randomization to the date of death from any cause",
        "successCriteria": "Statistically significant improvement in OS (only formally tested if primary endpoint is met)",
        "sourceText": "Since the primary endpoint was not met the key secondary endpoint OS was not formally statistically tested."
      },
      {
        "id": "ep_3",
        "name": "Safety: Treatment Related Adverse Events (TRAEs)",
        "endpointType": "Secondary",
        "inputs": [
          "Adverse Event (AE) grade",
          "Relationship to study drug"
        ],
        "timeWindow": {
          "reference": "First dose of study treatment",
          "duration": "Throughout study duration"
        },
        "algorithm": "(Number of patients with at least one TRAE / Total patients in treatment arm) * 100",
        "successCriteria": "Manageable safety profile with dose interruptions and reductions",
        "sourceText": "The safety data demonstrated that the treatment related AEs (TRAEs) all grades occurred in 98.5% vs. 87.5% of patients, and ≥ grade 3 in 54.7% vs. 33.3% of patients"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Progression-Free Survival (PFS)",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of randomization",
          "Date of first documented progression",
          "Date of death"
        ],
        "derivationRule": "The time from the date of randomization to the date of the first documented progression or death due to any cause. If a patient has not progressed or died, PFS is censored at the date of the last adequate tumor assessment.",
        "baselineDefinition": "Date of randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "Per RECIST 1.1 schedule until 01-Jul-2020",
        "imputationRule": "Censoring at last adequate tumor assessment for missing events",
        "unit": "Months"
      },
      {
        "id": "dv_2",
        "name": "Change from Baseline in Safety Laboratory Parameters",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "Safety laboratory value",
          "Baseline laboratory value"
        ],
        "derivationRule": "post_baseline_value - baseline_value",
        "baselineDefinition": "Last non-missing value prior to first dose of study treatment",
        "baselineVisit": "Day 1",
        "analysisWindow": "Per study visit schedule (Table 7-1, 7-2, 7-3)",
        "imputationRule": "None specified for safety labs",
        "unit": "As per laboratory standard"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Molecular Pre Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Molecular Pre Screening",
        "Screening",
        "Treatment Phase",
        "End Of Treatment",
        "Safety Follow Up",
        "Efficacy Follow Up",
        "Survival Follow Up",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Molecular Pre Screening",
          "toState": "Screening",
          "trigger": "Progress to Screening"
        },
        {
          "fromState": "Screening",
          "toState": "Treatment Phase",
          "trigger": "Progress to Treatment Phase"
        },
        {
          "fromState": "Treatment Phase",
          "toState": "End Of Treatment",
          "trigger": "Progress to End Of Treatment"
        },
        {
          "fromState": "End Of Treatment",
          "toState": "Safety Follow Up",
          "trigger": "Progress to Safety Follow Up"
        },
        {
          "fromState": "Safety Follow Up",
          "toState": "Efficacy Follow Up",
          "trigger": "Progress to Efficacy Follow Up"
        },
        {
          "fromState": "Efficacy Follow Up",
          "toState": "Survival Follow Up",
          "trigger": "Progress to Survival Follow Up"
        },
        {
          "fromState": "Treatment Phase",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "End Of Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Molecular Pre Screening": "MOLECULAR_PRE_SCREENING",
        "Screening": "SCREENING",
        "Treatment Phase": "TREATMENT_PHASE",
        "End Of Treatment": "END_OF_TREATMENT",
        "Safety Follow Up": "SAFETY_FOLLOW_UP",
        "Efficacy Follow Up": "EFFICACY_FOLLOW_UP",
        "Survival Follow Up": "SURVIVAL_FOLLOW_UP",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_llm_1",
        "treatmentName": "PDR001 (spartalizumab)",
        "frequency": "Q4W",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "Until disease progression or unacceptable toxicity",
        "doseModifications": [
          "Dose modifications and management guidelines for infusion reactions",
          "General dose modification instructions for PDR001 or placebo"
        ]
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Dabrafenib",
        "frequency": "BID",
        "route": "Oral",
        "startDay": 1,
        "durationDescription": "Until disease progression or unacceptable toxicity",
        "doseModifications": [
          "Dose modifications and management guidelines for adverse events common to PDR001, dabrafenib and trametinib"
        ]
      },
      {
        "id": "dosing_llm_3",
        "treatmentName": "Trametinib",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "durationDescription": "Until disease progression or unacceptable toxicity",
        "doseModifications": [
          "Dose modifications and management guidelines for adverse events common to PDR001, dabrafenib and trametinib"
        ]
      },
      {
        "id": "dosing_llm_4",
        "treatmentName": "Placebo",
        "frequency": "Q4W",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "Until disease progression or unacceptable toxicity",
        "doseModifications": [
          "General dose modification instructions for PDR001 or placebo"
        ]
      }
    ],
    "visitWindows": [
      {
        "id": "visit_2",
        "visitName": "Screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening phase",
        "sourceText": "Screening phase.....................................................................................74 4.1.2 Treatment phase............................................................................"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "Overview of dabrafenib and trametinib.................................................53 2 Rationale ..................................................................................................."
      },
      {
        "id": "visit_3",
        "visitName": "End of treatment",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 3,
        "epoch": "End of treatment",
        "sourceText": "End of treatment ....................................................................................75 4.1.4 Safety follow-up.........................................................................."
      },
      {
        "id": "visit_6",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "Post baseline imaging assessments (Section 7.2.1.2) updated to reflect requirements following final PFS analysis •"
      },
      {
        "id": "visit_7",
        "visitName": "Visit 600",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "combination with dabrafenib and trametinib in patients with untreated BRAF V600 mutant melanoma. Results from KEYNOTE-022 Part 3 (Ascierto et al., 2018b) suggest a 5 months delayed treatment effect fo"
      },
      {
        "id": "visit_8",
        "visitName": "end of study",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "Clarified definition of end of study (Section 4.3) in the case that statistically significant interim (at the time of the primary PFS analysis) or final OS results are demonstrated. •"
      },
      {
        "id": "visit_15",
        "visitName": "Visit 1",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "primary endpoint was PFS based on investigator assessed response by RECIST v1.1. The final PFS analysis showed that the study did not meet its primary endpoint of investigator- assessed PFS. The combi"
      },
      {
        "id": "visit_llm_1",
        "visitName": "Molecular pre-screening",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Pre-screening"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Treatment Period Visits",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 4,
        "epoch": "Treatment phase"
      },
      {
        "id": "visit_llm_6",
        "visitName": "Safety follow-up",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 6,
        "epoch": "Safety follow-up"
      },
      {
        "id": "visit_llm_7",
        "visitName": "Efficacy follow-up",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 7,
        "epoch": "Efficacy follow-up"
      },
      {
        "id": "visit_llm_8",
        "visitName": "Survival follow-up",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 8,
        "epoch": "Survival follow-up"
      },
      {
        "id": "visit_5",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 13,
        "epoch": "Treatment phase",
        "sourceText": "Subject numbering, treatment assignment or randomization...............................129 6.5.1 Subject numbering...............................................................................129"
      },
      {
        "id": "visit_9",
        "visitName": "Day 8",
        "targetDay": 8,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "sourceText": "at Cycle 1 Day 8 for Part 2 (Table 7-10). • Added language to allow request for additional archival tumor tissue in case the sample"
      },
      {
        "id": "visit_10",
        "visitName": "Day 15",
        "targetDay": 15,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": false,
        "visitNumber": 15,
        "sourceText": "Added an additional optional tumor biopsy collection at Cycle 1 Day 15 for part 3 to expand biomarker analyses with samples collected in part 3 (Tables 7-3; Table 7-16); (Section 7.2.4.1)"
      },
      {
        "id": "visit_14",
        "visitName": "Day 18",
        "targetDay": 18,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 16,
        "sourceText": "induction of its own metabolism. Mean accumulation AUC Day 18/Day 1 ratios was 0.73. Dabrafenib binds to human plasma protein and is 99.7% bound. The metabolism of dabrafenib is primarily mediated by "
      },
      {
        "id": "visit_11",
        "visitName": "Day 29",
        "targetDay": 29,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 17,
        "sourceText": "The start day of PDR001 for part 1 DL-1b was revised from ‘from Day 29’ to ‘starting at C2D1 (Day 29)’ in Table 6-2 to align with Table 6-5. •"
      },
      {
        "id": "visit_12",
        "visitName": "Day 31",
        "targetDay": 31,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 18,
        "sourceText": "medication’ and the beginning of the ‘post treatment’ was changed to ‘at day 31 after last dose of study medication’. Inserted a paragraph stating that summaries for deaths, all AEs, and all SAEs coll"
      },
      {
        "id": "visit_4",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 19,
        "sourceText": "Safety follow-up....................................................................................75 4.1.5 Efficacy follow-up........................................................................."
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1:1",
      "method": "Stratified block randomization",
      "centralRandomization": true,
      "blockSize": "Not specified in provided text",
      "stratificationFactors": [
        {
          "id": "strat_llm_1",
          "name": "BRAF mutation status",
          "categories": [
            "BRAF V600-mutant",
            "BRAF wild-type"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Prior anti-PD-1/PD-L1 therapy for unresectable or metastatic melanoma",
          "categories": [
            "Yes",
            "No"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_3",
          "name": "LDH level",
          "categories": [
            "≤ ULN",
            "> ULN"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "Novartis\nConfidential\nPage 4 of 289\nAmended Protocol Version 07 (Clean)\nProtocol No. CPDR001F2301\n6.3.6\nFollow-up for toxicities.......................................................................1"
    }
  }
}